A citation-based method for searching scientific literature

Chin Meng Khoo, Chaicharn Deerochanawong, Siew Pheng Chan, Bien Matawaran, Wayne Huey-Herng Sheu, Juliana Chan, Ambrish Mithal, Andrea Luk, Ketut Suastika, Kun-Ho Yoon, Linong Ji, Nguyen Huu Man, Carol Pollock. Diabetes Obes Metab 2021
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
100

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry.
X L Yang, W Y So, A P S Kong, P Clarke, C S Ho, C W K Lam, M H L Ng, R R Lyu, D D Yin, C C Chow,[...]. Diabetologia 2006
53
50

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
Sophia Zoungas, Hisatomi Arima, Hertzel C Gerstein, Rury R Holman, Mark Woodward, Peter Reaven, Rodney A Hayward, Timothy Craven, Ruth L Coleman, John Chalmers. Lancet Diabetes Endocrinol 2017
192
50

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
Peter Gaede, Pernille Vedel, Nicolai Larsen, Gunnar V H Jensen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2003
50

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
Amanda I Adler, Richard J Stevens, Sue E Manley, Rudy W Bilous, Carole A Cull, Rury R Holman. Kidney Int 2003
50

International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries.
Beverley Balkau, John E Deanfield, Jean-Pierre Després, Jean-Pierre Bassand, Keith A A Fox, Sidney C Smith, Philip Barter, Chee-Eng Tan, Luc Van Gaal, Hans-Ulrich Wittchen,[...]. Circulation 2007
444
50

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
233
50

Standards of care for type 2 diabetes in China.
Jianping Weng, Linong Ji, Weiping Jia, Juming Lu, Zhiguang Zhou, Dajin Zou, Dalong Zhu, Liming Chen, Li Chen, Lixin Guo,[...]. Diabetes Metab Res Rev 2016
168
50

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.
Juliana C N Chan, Nelson M S Wat, Wing-Yee So, Karen S L Lam, Chin-Teong Chua, Kok-Seng Wong, Zaki Morad, Tania Z Dickson, Darcy Hille, Zhongxin Zhang,[...]. Diabetes Care 2004
58
50


All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan.
Chi Pang Wen, Ting Yuan David Cheng, Min Kuang Tsai, Yen Chen Chang, Hui Ting Chan, Shan Pou Tsai, Po Huang Chiang, Chih Cheng Hsu, Pei Kun Sung, Yi Hua Hsu,[...]. Lancet 2008
633
50

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
132
50

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Remo H M Furtado, Marc P Bonaca, Itamar Raz, Thomas A Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
114
50

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.
Ravi Retnakaran, Carole A Cull, Kerensa I Thorne, Amanda I Adler, Rury R Holman. Diabetes 2006
563
50

Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort.
Roseanne O Yeung, Yuying Zhang, Andrea Luk, Wenying Yang, Leorino Sobrepena, Kun-Ho Yoon, S R Aravind, Wayne Sheu, Thy Khue Nguyen, Risa Ozaki,[...]. Lancet Diabetes Endocrinol 2014
130
50

New pharmacological strategies for protecting kidney function in type 2 diabetes.
Marcel H A Muskiet, David C Wheeler, Hiddo J L Heerspink. Lancet Diabetes Endocrinol 2019
36
50

Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study.
Daisuke Ito, Kazuyuki Inoue, Takashi Sumita, Keiko Hamaguchi, Kimie Kaneko, Morifumi Yanagisawa, Kouichi Inukai, Ikuo Inoue, Mitsuhiko Noda, Akira Shimada. J Clin Med Res 2018
4
50

High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India.
Ambady Ramachandran, Simon Mary, Annasami Yamuna, Narayanasamy Murugesan, Chamukuttan Snehalatha. Diabetes Care 2008
177
50


Prevalence of chronic kidney disease in the Japanese general population.
Enyu Imai, Masaru Horio, Tsuyoshi Watanabe, Kunitoshi Iseki, Kunihiro Yamagata, Shigeko Hara, Nobuyuki Ura, Yutaka Kiyohara, Toshiki Moriyama, Yasuhiro Ando,[...]. Clin Exp Nephrol 2009
338
50

Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Hiroyuki Takashima, Yoshinori Yoshida, Chinami Nagura, Tetsuya Furukawa, Ritsukou Tei, Takashi Maruyama, Noriaki Maruyama, Masanori Abe. Diab Vasc Dis Res 2018
14
50

Effect of a multifactorial intervention on mortality in type 2 diabetes.
Peter Gaede, Henrik Lund-Andersen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2008
50

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
Hiddo J L Heerspink, Mehul Desai, Meg Jardine, Dainius Balis, Gary Meininger, Vlado Perkovic. J Am Soc Nephrol 2017
191
50

Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Avivit Cahn, Cheli Melzer-Cohen, Rena Pollack, Gabriel Chodick, Varda Shalev. Diabetes Obes Metab 2019
34
50


SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
Silvio E Inzucchi, Bernard Zinman, Christoph Wanner, Roberto Ferrari, David Fitchett, Stefan Hantel, Rosa-Maria Espadero, Hans-Jürgen Woerle, Uli C Broedl, Odd Erik Johansen. Diab Vasc Dis Res 2015
250
50

Update on Diabetic Nephropathy: Core Curriculum 2018.
Kausik Umanath, Julia B Lewis. Am J Kidney Dis 2018
210
50

Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study.
Takeshi Osonoi, Maki Gouda, Mamiko Kubo, Kenji Arakawa, Toshio Hashimoto, Masanori Abe. Diabetes Technol Ther 2018
10
50


Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.
Jens Oellgaard, Peter Gæde, Peter Rossing, Frederik Persson, Hans-Henrik Parving, Oluf Pedersen. Kidney Int 2017
49
50

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
George L Bakris, Rajiv Agarwal, Juliana C Chan, Mark E Cooper, Ron T Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E Schmieder, Christina Nowack,[...]. JAMA 2015
291
50

Genetic associations in diabetic nephropathy: a meta-analysis.
A L Mooyaart, E J J Valk, L A van Es, J A Bruijn, E de Heer, B I Freedman, O M Dekkers, H J Baelde. Diabetologia 2011
151
50

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki, Masayuki Kato, Sumie Okahata, Hisayuki Katsuyama, Mikiko Haraguchi, Ai Morita, Ken Ohashi, Kazuo Hara,[...]. Lancet Diabetes Endocrinol 2017
122
50

Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.
Connor A Emdin, Kazem Rahimi, Bruce Neal, Thomas Callender, Vlado Perkovic, Anushka Patel. JAMA 2015
401
50

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner,[...]. JAMA 2019
448
50


Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, Christopher P Cannon, Bruce Neal, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris,[...]. Circulation 2019
105
50



Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
50

Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Masakazu Haneda, Yutaka Seino, Nobuya Inagaki, Kohei Kaku, Takashi Sasaki, Atsushi Fukatsu, Haruka Kakiuchi, Yuri Sato, Soichi Sakai, Yoshishige Samukawa. Clin Ther 2016
38
50

Racial and ethnic differences in microalbuminuria prevalence in a diabetes population: the pathways study.
Bessie A Young, Wayne J Katon, Michael Von Korff, Greg E Simon, Elizabeth H B Lin, Paul S Ciechanowski, Terry Bush, Malia Oliver, Evette J Ludman, Edward J Boyko. J Am Soc Nephrol 2005
74
50

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
Daiji Kawanami, Keiichiro Matoba, Yusuke Takeda, Yosuke Nagai, Tomoyo Akamine, Tamotsu Yokota, Kazunori Sango, Kazunori Utsunomiya. Int J Mol Sci 2017
77
50

Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.
Nathan R Hill, Samuel T Fatoba, Jason L Oke, Jennifer A Hirst, Christopher A O'Callaghan, Daniel S Lasserson, F D Richard Hobbs. PLoS One 2016
50

Prevalence and factors associated with CKD: a population study from Beijing.
LuXia Zhang, PuHong Zhang, Fang Wang, Li Zuo, Ying Zhou, Ying Shi, Gang Li, ShuFang Jiao, ZeJun Liu, WanNian Liang,[...]. Am J Kidney Dis 2008
215
50

Inpatient screening for albuminuria and retinopathy to predict long-term mortality in type 2 diabetic patients: a retrospective cohort study.
Ya-Mei Hsieh, Wen-Jane Lee, Wayne H-H Sheu, Yu-Hsuan Li, Shih-Yi Lin, I-Te Lee. Diabetol Metab Syndr 2017
8
50

Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study.
Jamie P Dwyer, Hans-Henrik Parving, Lawrence G Hunsicker, Moti Ravid, Giuseppe Remuzzi, Julia B Lewis. Cardiorenal Med 2012
64
50

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
252
50

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B M Brenner, M E Cooper, D de Zeeuw, W F Keane, W E Mitch, H H Parving, G Remuzzi, S M Snapinn, Z Zhang, S Shahinfar. N Engl J Med 2001
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.